BICO Group ABCLLKF -7.36%63 EBITDA Margin % is -10.06% as of Mar. 2026. GuruFocus rates CLLKF with a GF Score™ of 63/100 and a GF Value™ of $3.69 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 816 Medical Devices & Instruments companies, BICO Group AB ranks worse than 62.25% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. BICO Group AB's EBITDA for the
three
months ended in Mar. 2026 was $-3.6 Mil. BICO Group AB's Revenue for the
three
months ended in Mar. 2026 was $35.4 Mil. Therefore, BICO Group AB's EBITDA margin for the quarter that ended in Mar. 2026 was -10.06%.
BICO Group AB (OTCPK:CLLKF) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
BICO Group AB EBITDA Margin % Related Terms
BICO Group AB EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for BICO Group AB's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CLLKF vs ABT, SYK, MDT: EBITDA Margin % Comparison
For the Medical Devices subindustry, BICO Group AB's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BICO Group AB EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, BICO Group AB's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where BICO Group AB's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BICO Group AB (CLLKF) has a EBITDA Margin % of -10.06% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on BICO Group AB and its competitors. According to the industry distribution chart, BICO Group AB ranks #508 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 62.3%.
Is BICO Group AB's EBITDA Margin % too high?
BICO Group AB's current EBITDA Margin % is -10.06%. Based on the distribution chart, BICO Group AB ranks #508 out of 816 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, BICO Group AB has a GF Score™ of 63/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BICO Group AB's EBITDA Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, BICO Group AB ranks #508 out of 816 companies for EBITDA Margin %. This places BICO Group AB in the lower half of its industry. The industry median EBITDA Margin % is 7.48. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on BICO Group AB and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BICO Group AB's current EBITDA Margin % is -10.06%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BICO Group AB stock overvalued right now?
Based on GuruFocus' analysis, BICO Group AB (CLLKF) is currently considered Possible Value Trap. The stock's GF Value™ is $3.69, compared to a current price of $1.76 — trading 52.2% below its estimated fair value. The current EBITDA Margin % is -10.06%. BICO Group AB's overall GF Score™ is 63/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For BICO Group AB (CLLKF), the current EBITDA Margin % is -10.06% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BICO Group AB (CLLKF) Overvalued in 2026?
Based on GuruFocus' analysis, BICO Group AB stock appears to be undervalued.
The current stock price of $1.76 is trading 52.2% below its estimated GF Value™ of $3.69.
GuruFocus considers BICO Group AB to be Possible Value Trap.
Key valuation signals for CLLKF:
EBITDA Margin %: -10.06%
GF Value™: $3.69 vs. price of $1.76 (52.2% below fair value)
No single metric tells the full story. See the CLLKF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BICO Group AB provides hardware, laboratory automation software, and products to automate and increase efficiency in workflows for pharma and biotech companies. Its portfolio includes automated workstations, lab automation software, microscopes and live-cell imaging, 3D cell culture and bioprinting, single-cell dispensing, liquid handling, mixing technologies, and consumables. The Group operates through two segments: Life Science Solutions, the maximum revenue generator, including CYTENA, DISPENDIX, Discover Echo, QInstruments, SCIENION, Cellenion, CELLINK, and BioMatrix, and Lab Automation, consisting of Biosero, which provides the Green Button Go Suite software and automation integration services.
63GF Score
Get the complete analysis for CLLKF
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLLKF has been successfully added to your 
